Premium Nahrungsergänzungsmittel | artgerecht

Ixazomib: Mechanism, Dosage & Side Effects

Ixazomib is an oral cancer drug belonging to the class of proteasome inhibitors, used in the treatment of multiple myeloma.

Regular tips about health Regular tips about health

Things worth knowing about "Ixazomib"

Ixazomib is an oral cancer drug belonging to the class of proteasome inhibitors, used in the treatment of multiple myeloma.

What is Ixazomib?

Ixazomib is a second-generation proteasome inhibitor and the first orally administered agent of this drug class. It is marketed under the brand name Ninlaro and is approved for the treatment of multiple myeloma – a malignant disease of plasma cells in the bone marrow. Ixazomib is administered as ixazomib citrate, which is rapidly converted to its active form in the body.

Indication

Ixazomib is approved in combination with lenalidomide and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior therapy. This three-drug combination has demonstrated efficacy in clinical trials in slowing disease progression and extending progression-free survival.

Mechanism of Action

Ixazomib selectively inhibits the 26S proteasome complex, a central cellular organelle responsible for degrading misfolded or damaged proteins. By blocking the proteasome, ubiquitinated proteins accumulate within cancer cells, leading to:

Endoplasmic reticulum stress
Activation of apoptotic signaling pathways (programmed cell death)
Inhibition of tumor cell proliferation

Myeloma cells are particularly vulnerable to this type of stress because they produce large quantities of antibodies and therefore rely heavily on a functional proteasome.

Dosage and Administration

Ixazomib is administered orally as hard capsules. The recommended dose is 4 mg once weekly on days 1, 8, and 15 of a 28-day treatment cycle. The capsule should be taken at least one hour before or two hours after a meal. Dose adjustments may be necessary in patients with renal impairment or hepatic disease. Treatment is continued until disease progression or unacceptable toxicity occurs.

Side Effects

Like all cancer medicines, ixazomib can cause side effects. The most common include:

Hematological effects: Thrombocytopenia (low platelet count), neutropenia, anemia
Gastrointestinal complaints: Nausea, diarrhea, constipation, vomiting
Peripheral neuropathy: Tingling, numbness, or pain in the hands and feet
Skin reactions: Rash, dry skin
Infections: Increased susceptibility to infections
Edema: Swelling, particularly in the legs

Serious adverse events such as severe thrombocytopenia, hepatotoxicity, and thrombotic microangiopathy are less common but require close monitoring.

Treatment Context and Clinical Studies

The approval of ixazomib was largely based on the TOURMALINE-MM1 study, a phase III trial demonstrating that the triple combination of ixazomib, lenalidomide, and dexamethasone significantly prolonged median progression-free survival compared to placebo plus lenalidomide and dexamethasone. As the first all-oral proteasome inhibitor regimen, ixazomib offers patients a more convenient treatment option compared to intravenously or subcutaneously administered alternatives such as bortezomib or carfilzomib.

Interactions and Precautions

Ixazomib is metabolized primarily by CYP3A4. Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine) may reduce the efficacy of ixazomib and should be avoided. Strong CYP3A4 inhibitors may increase drug exposure. Regular blood count monitoring is recommended during therapy. Ixazomib is contraindicated during pregnancy and breastfeeding.

References

Moreau P et al. - Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. New England Journal of Medicine, 2016; 374(17):1621–1634.
European Medicines Agency (EMA) - Ninlaro (Ixazomib): Summary of Product Characteristics. EMA, 2016. Available at: www.ema.europa.eu
Rajkumar SV, Kumar S - Multiple Myeloma: Diagnosis and Treatment. Mayo Clinic Proceedings, 2016; 91(1):101–119.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.